Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in treatment-experienced patients. In the DUET 1 and 2 trials, 1203 highly treatment-experienced patients were randomized to etravirine or placebo, in combination with darunavir/ritonavir and optimized b...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Mark, Hill, Andrew, van Delft, Yvon, Moecklinghoff, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955667/
https://www.ncbi.nlm.nih.gov/pubmed/24715982
http://dx.doi.org/10.1155/2014/636584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955667/
https://www.ncbi.nlm.nih.gov/pubmed/24715982
http://dx.doi.org/10.1155/2014/636584

Ejemplares similares